Australian Clinical Labs Limited (ASX:ACL)
Australia
· Delayed Price · Currency is AUD 2.190
-0.010 (-0.45%)
At close: Mar 9, 2026
Australian Clinical Labs Ratios and Metrics
Market cap in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2017 |
| Market Capitalization | 415 | 540 | 503 | 694 | 922 | 686 | Upgrade
|
| Market Cap Growth | -43.73% | 7.36% | -27.51% | -24.69% | 34.33% | - | Upgrade
|
| Enterprise Value | 707 | 834 | 805 | 1,001 | 1,160 | 940 | Upgrade
|
| Last Close Price | 2.19 | 2.69 | 2.34 | 3.09 | 3.70 | 2.67 | Upgrade
|
| PE Ratio | 15.54 | 16.66 | 21.03 | 19.34 | 5.17 | 11.37 | Upgrade
|
| Forward PE | 12.54 | 13.94 | 13.83 | 15.92 | 9.64 | 7.42 | Upgrade
|
| PS Ratio | 0.56 | 0.73 | 0.72 | 1.00 | 0.93 | 1.06 | Upgrade
|
| PB Ratio | 2.74 | 3.14 | 2.83 | 4.02 | 3.96 | 8.38 | Upgrade
|
| P/TBV Ratio | - | 87.92 | 39.99 | 95.82 | 13.75 | - | Upgrade
|
| P/FCF Ratio | 2.65 | 3.10 | 3.29 | 5.08 | 3.51 | 4.75 | Upgrade
|
| P/OCF Ratio | 2.52 | 2.96 | 3.15 | 4.83 | 3.25 | 4.46 | Upgrade
|
| PEG Ratio | 1.65 | 0.74 | 3.00 | - | - | - | Upgrade
|
| EV/Sales Ratio | 0.96 | 1.13 | 1.16 | 1.44 | 1.17 | 1.45 | Upgrade
|
| EV/EBITDA Ratio | 3.47 | 10.26 | 10.55 | 12.56 | 4.05 | 6.80 | Upgrade
|
| EV/EBIT Ratio | 10.30 | 12.27 | 12.87 | 15.35 | 4.24 | 7.34 | Upgrade
|
| EV/FCF Ratio | 4.51 | 4.79 | 5.26 | 7.32 | 4.42 | 6.51 | Upgrade
|
| Debt / Equity Ratio | 2.09 | 1.69 | 1.74 | 1.83 | 1.13 | 3.71 | Upgrade
|
| Debt / EBITDA Ratio | 1.55 | 1.42 | 1.62 | 1.68 | 0.69 | 1.41 | Upgrade
|
| Debt / FCF Ratio | 2.01 | 1.67 | 2.02 | 2.31 | 1.00 | 2.11 | Upgrade
|
| Net Debt / Equity Ratio | 1.93 | 1.56 | 1.59 | 1.71 | 1.01 | 3.27 | Upgrade
|
| Net Debt / EBITDA Ratio | 3.58 | 3.30 | 3.70 | 3.71 | 0.82 | 1.94 | Upgrade
|
| Net Debt / FCF Ratio | 1.86 | 1.54 | 1.84 | 2.16 | 0.89 | 1.85 | Upgrade
|
| Asset Turnover | 1.29 | 1.27 | 1.19 | 1.16 | 1.79 | 1.52 | Upgrade
|
| Inventory Turnover | 28.26 | 28.99 | 27.72 | 25.32 | 32.71 | 32.71 | Upgrade
|
| Quick Ratio | 0.42 | 0.44 | 0.52 | 0.51 | 0.53 | 0.60 | Upgrade
|
| Current Ratio | 0.59 | 0.56 | 0.64 | 0.62 | 0.64 | 0.71 | Upgrade
|
| Return on Equity (ROE) | 16.68% | 18.77% | 13.84% | 17.79% | 113.46% | 80.04% | Upgrade
|
| Return on Assets (ROA) | 7.48% | 7.28% | 6.67% | 6.75% | 30.79% | 18.82% | Upgrade
|
| Return on Invested Capital (ROIC) | 9.94% | 10.29% | 8.98% | 10.40% | 46.95% | 29.52% | Upgrade
|
| Return on Capital Employed (ROCE) | 18.80% | 19.00% | 16.20% | 16.70% | 68.00% | 40.20% | Upgrade
|
| Earnings Yield | 6.35% | 6.00% | 4.76% | 5.17% | 19.34% | 8.80% | Upgrade
|
| FCF Yield | 37.80% | 32.28% | 30.42% | 19.70% | 28.51% | 21.04% | Upgrade
|
| Dividend Yield | 5.68% | 4.64% | 5.14% | 4.53% | 14.34% | 5.33% | Upgrade
|
| Payout Ratio | 92.80% | 76.92% | 83.35% | 269.85% | 13.59% | 69.57% | Upgrade
|
| Buyback Yield / Dilution | 6.50% | 4.63% | 0.82% | 0.18% | -32.47% | -4.65% | Upgrade
|
| Total Shareholder Return | 12.19% | 9.28% | 5.95% | 4.71% | -18.13% | 0.68% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.